1. Home
  2. EKSO vs LGVN Comparison

EKSO vs LGVN Comparison

Compare EKSO & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ekso Bionics Holdings Inc.

EKSO

Ekso Bionics Holdings Inc.

HOLD

Current Price

$11.80

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.77

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EKSO
LGVN
Founded
2005
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
34.0M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
EKSO
LGVN
Price
$11.80
$0.77
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$9.50
$3.00
AVG Volume (30 Days)
55.1K
383.9K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
41.76
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
$81.23
N/A
Revenue Next Year
$7.29
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.88
$0.48
52 Week High
$13.50
$1.80

Technical Indicators

Market Signals
Indicator
EKSO
LGVN
Relative Strength Index (RSI) 60.17 44.67
Support Level $8.30 $0.74
Resistance Level $12.39 $0.86
Average True Range (ATR) 0.86 0.07
MACD 0.15 0.01
Stochastic Oscillator 79.44 49.28

Price Performance

Historical Comparison
EKSO
LGVN

About EKSO Ekso Bionics Holdings Inc.

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: